Moreover, no correlation was observed between MDM2 and apoptotic outcome of nutlin-3 in sarcomas [88], and a clinical trial of patients with MDM2-amplified liposarcomas yielded a poor response to MDM2 inhibition as monotherapy [35], suggesting that MDM2 amplification is not a universal marker for therapy response. Here, MDM2 is linked to sarcoma.